ColoSense is designed for adults aged 45 to 85 years who are considered at average risk for colorectal cancer.
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of ColoSense®, the only RNA-based at-home test for colorectal ...
WASHINGTON (AP) — In a story March 24 about colon cancer screening tests, The Associated Press reported erroneously that the Colosure test from LabCorp is approved by the Food and Drug Administration.
ST. LOUIS--(BUSINESS WIRE)--Geneoscopy Inc., a life sciences company focused on the development of diagnostic tests for gastrointestinal health, today announced a strategic collaboration with Labcorp ...